#CardioTwitter
LightNews LightNews
med-iq.bsky.social
#CardioTwitter
#AHA2026
#MedIQScientificSessions26
November 10, 2026 at 9:54 PM
med-iq.bsky.social
Lots of changes in the characteristics of inpatients with ATTR-CM

#CardioTwitter
#AHA2026
#MedIQScientificSessions26
November 10, 2026 at 9:54 PM
med-iq.bsky.social
@sarahcud presented the long term outcomes of vutrisiran from the HELIOS-B OLE trial

#CardioTwitter
#AHA2026
#MedIQScientificSessions26
November 10, 2026 at 9:54 PM
med-iq.bsky.social
Favorable myocardial structural changes in response to eplontersen vs placebo in the CARDIO-TTRansform trial

#CardioTwitter
#AHA2026
#MedIQScientificSessions26
November 10, 2026 at 9:54 PM
med-iq.bsky.social
Eplontersen echo study showing attenuation of progression of various echo metrics in monotherapy

ahajournals.org/doi/10.1161/...

#CardioTwitter
#AHA2026
#MedIQScientificSessions26
November 10, 2026 at 9:54 PM
med-iq.bsky.social
Acoramidis is associated with significant benefit accounting for pas events evaluated in this multistate modeling

#CardioTwitter
#AHA2026
#MedIQScientificSessions26
November 10, 2026 at 9:54 PM
med-iq.bsky.social
Sex Differences at Diagnosis Among Patients with Hereditary and Wild-Type Transthyretin Amyloidosis: Analysis from the ConTTRibute Study

#CardioTwitter
#AHA2026
#MedIQScientificSessions26
November 10, 2026 at 9:54 PM
med-iq.bsky.social
Women with ATTR-CM are underrecognized using conventional scores in a HF cohort. Authors developed an ML model

#CardioTwitter
#AHA2026
#MedIQScientificSessions26
November 10, 2026 at 9:54 PM
med-iq.bsky.social
A single center CPET substudy of HELIOS-B - vurtisiran vs placebo. An excellent evaluation into functional exercise testing in a complex disease

#CardioTwitter
#AHA2026
#MedIQScientificSessions26
November 10, 2026 at 9:54 PM
med-iq.bsky.social
Filippo Ravalli presented on srum TTR increase on tafamidis is a good thing. Relationship between increase by 5 vs not and outcomes.

#CardioTwitter
#AHA2026
#MedIQScientificSessions26
November 10, 2026 at 9:54 PM
med-iq.bsky.social
Extending the usefulness of NTproBNP in ATTR-CM, which rises prior to a HF event and declines on acoramidis post while have a different behavior on placebo.

#CardioTwitter
#AHA2026
#MedIQScientificSessions26
November 10, 2026 at 9:54 PM
med-iq.bsky.social
@maz_hanna presented on the totality of HF events and how acoramidis improved these fairly early on (45% reduction starting early within a few weeks). A post hoc analysis.

#CardioTwitter
#AHA2026
#MedIQScientificSessions26
November 10, 2026 at 9:54 PM
med-iq.bsky.social
@sarahcud on new trials in ATTR-CM

I never thought I'd see a trial of 2250 patients in this disease. Just incredible progress here. Lots of work. Grateful to patients who participate

#CardioTwitter
#AHA2026
#MedIQScientificSessions26
November 10, 2026 at 9:54 PM
drpnil.bsky.social
Out in @jamacardiology.com : Our GBD 2023 shows global heart failure hit 56M cases (+124.6% since 1990). Etiologies shift from congenital & RHD in youth to alcohol in midlife and IHD/HHD in older adults.

🔗 bit.ly/3W78f3f

#CardioTwitter #HeartFailure #GlobalHealth
Global, Regional, and National Burden of Heart Failure, 1990-2023
This cross-sectional study estimates the global burden of heart failure by using methodologies from the Global Burden of Diseases, Injuries, and Risk Factors Study to integrate multiple sources from 2...
bit.ly
November 2, 2026 at 7:27 PM
med-iqcardiology.bsky.social
@rohan_khera on the use of a novel AI-ECG algorithm in the ATTRIBUTE-CM trial

#cardiotwitter
#ESC2026
#ESCCongress
#ESCCongress2026
#ESCCongressMedIQ
August 31, 2026 at 9:56 PM
jonmagne.bsky.social
https://academic.oup.com/eurheartj/article/40/20/1640/5193507#.XOTtWzix9Gw.twitter @ESC_Journals #cardiotwitter @CERG_NTNU
November 16, 2024 at 6:06 PM
jonmagne.bsky.social
@theHUNTstudy @AndreasGevaert @cpgale3 @ThijsEijsvogels @MorsethBente @EsmeeBakker__ @strain_rate @load_dependent @marinorgy @StefanoNistri @TheBJCA @venkmurthy @sol_vidalalmela @ErinMichos @Ulf_Ekelund @SilCastelletti @ProfessorHalle @DrMarthaGulati #cardiotwitter
November 16, 2024 at 4:47 PM
jonmagne.bsky.social
https://academic.oup.com/ehjcimaging/article/12/11/826/2396794
#cardiotwitter
1/x
November 16, 2024 at 4:47 PM
jonmagne.bsky.social
🧵1/x

📎https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehab721/6422750?searchresult=1 #CardioTwitter
November 16, 2024 at 3:50 PM
jonmagne.bsky.social
Busy last months, but nice to see inclusion to NEXAF trial on exercise in atrial fibrillation getting up to speed. First 40 loop recorders implanted and first patients randomised to exercise well into the intervention already! Only a few hundred more to go.. #CardioTwitter
November 16, 2024 at 2:35 PM
jonmagne.bsky.social
📎
https://www.sciencedirect.com/science/article/pii/S1936878X22007513?via%3Dihub
#cardiotwitter #echofirst
ScienceDirect
www.sciencedirect.com
November 16, 2024 at 12:17 PM
jonmagne.bsky.social
Could indexing LVEDV to absolute VO2peak (L/min) be the 🏆in assessing LV size?

In our latest paper we show how LVEDV/VO2peak discriminates LV enlargement in heart failure from physiological enlargement in athletes. New index for heart failure diagnostics? ⬇️🧵#cardiotwitter
November 16, 2024 at 12:00 PM
jonmagne.bsky.social


📎https://academic.oup.com/ehjcimaging/advance-article-abstract/doi/10.1093/ehjci/jead050/7083140?redirectedFrom=fulltext&login=false

📎https://academic.oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jead034/7129333 #cardiotwitter #echofirst #sportscardiology
November 16, 2024 at 12:00 PM
jonmagne.bsky.social
So cool that our latest paper on indexing the LV to VO2peak is featured as "Editor's choice" in the current issue of the EHJ Cardiovascular Imaging!
https://academic.oup.com/ehjcimaging/article/24/6/721/7129333?login=true @ESC_Journals #CardioTwitter #echofirst
November 16, 2024 at 11:44 AM
jonmagne.bsky.social
Finally got around to read this very nice paper by @mugander et al addressing various methods for indexing #echofirst measures. Huge kudos to the great work and for addressing the topic! A few thoughts from me on some of the findings 1/n🧵 #cardiotwitter...
November 16, 2024 at 9:20 AM